Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:5.99.1.2 (
topoisomerase
)
9,166
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We had previously shown that 10,11-methylenedioxy-20-(RS)-camptothecin (MDO-CPT) is a more potent inhibitor of purified DNA topoisomerase I than 20-(S)-camptothecin (CPT). The current studies compared the cytotoxicity and DNA damage induced by MDO-CPT and CPT in the human colon carcinoma cell line, HT-29. MDO-CPT was 7- to 10-fold more potent than CPT both for cytotoxicity (ID50 = 25 vs. 180 nM) and production of DNA single-strand breaks (SSB). Kinetics of SSB formation and reversal were similar for MDO-CPT and CPT. DNA-protein crosslinks (DPC) were also produced by both drugs with a SSB/DPC ratio of 1/1. Moreover, no SSB were detected under non-deproteinizing conditions, indicating that both CPT and MDO-CPT produced protein-linked DNA single-strand breaks. A good correlation between cytotoxic potency and protein-linked DNA single-strand break production was observed for CPT and MDO-CPT, implying a causal relationship between drug-induced cytotoxicity and
topoisomerase I
inhibition. The sensitivity of human colon HT-29 cancer cells to camptothecins may be a selective phenomenon since these cells normally express natural resistance to current chemotherapeutic drugs, including
topoisomerase
II inhibitors.
...
PMID:10,11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cells. 217 90
Cultured rat mesangial cells contain high affinity endothelin (ET) receptors at high densities. Exposure of these cells to ET resulted in a transient activation of
topoisomerase I
extractable activity, which reached its maximum value at approximately 2 min and returned to basal value after approximately 10 min of treatment. The activation of this enzyme was dependent upon the concentration of ET added. Incubation of the cells with pertussis toxin inhibited ET-induced increases in
topoisomerase I
activity in a concentration-dependent manner, suggesting that involvement of pertussis toxin-sensitive GTP-binding protein in ET-mediated action. Endothelin had no detectable effect upon extractable
topoisomerase
II activity.
...
PMID:Inhibition of endothelin-mediated topoisomerase I activation by pertussis toxin. 217 62
Exposure of infected CV-1 cells to specific type I and type II
topoisomerase
poisons caused strong protein association with distinct subsets of simian virus 40 (SV40) DNA replication intermediates. On the basis of the known specificity and mechanisms of action of these drugs, the proteins involved are assumed to be the respective topoisomerases. Camptothecin, a
topoisomerase I
poison, caused strong protein association with form II (relaxed circular) and form III (linear) viral genomes and replication intermediates having broken DNA replication forks but not with form I (superhelical) viral DNA or normal late replication intermediates which were present. In contrast, type II
topoisomerase
poisons caused completely replicated forms and late viral replication forms to be tightly bound to protein--some to a greater extent than others. Different type II
topoisomerase
inhibitors caused distinctive patterns of protein association with the replication intermediates present. Both intercalating and nonintercalating type II
topoisomerase
poisons caused a small amount of form I (superhelical) SV40 DNA to be protein-associated in vivo. The protein complex with form I viral DNA was entirely drug-dependent and strong, but apparently noncovalent. The protein associated with form I DNA may represent a drug-stabilized "topological complex" between type II
topoisomerase
and SV40 DNA.
...
PMID:Patterns of strongly protein-associated simian virus 40 DNA replication intermediates resulting from exposures to specific topoisomerase poisons. 217 89
Purified type I
topoisomerase
from calf thymus as well as nuclear and cytoplasmic extracts from EGF-stimulated human and mouse fibroblasts in cell culture efficiently convert supercoiled plasmid DNA to the relaxed form. The purified IgG fraction from the sera of Japanese patients with the rheumatic disease scleroderma were shown to inhibit this relaxation activity. Thus, these patients likely produce autoantibodies to
topoisomerase I
. In addition, the human, bovine and murine enzymes share antigenic determinants recognized by the antisera.
...
PMID:Inhibition of topoisomerase I by antibodies in sera from scleroderma patients. 243 27
Yeast strains with mutations in the genes for DNA topoisomerases I and II have been identified previously. The
topoisomerase
II mutants (top2) are conditional-lethal, temperature-sensitive mutants defective in the termination of DNA replication and the segregation of daughter chromosomes. The
topoisomerase I
mutants (top1), including strains with null mutations, are viable and exhibit no obvious growth defects, demonstrating that DNA topoisomerase I is not essential for viability in yeast. In contrast to the single mutants, top1 top2 double mutants grow poorly at the permissive temperature and stop DNA and ribosomal RNA synthesis at the restrictive temperature. Transfer RNA synthesis remains relatively normal. The rate of polyA+ RNA synthesis is down about 3-fold in the double mutant at the non-permissive temperature but the synthesis of three specific RNA polymerase II transcripts is unaffected. The results suggest that DNA replication and at least ribosomal RNA synthesis require an active
topoisomerase
, presumably to act as a swivel to relieve torsional stress, and that either
topoisomerase
can perform the required function (except for termination of DNA replication where
topoisomerase
II is required).
...
PMID:DNA topoisomerase activity is required as a swivel for DNA replication and for ribosomal RNA transcription. 244 27
A chromatographic method for the rapid isolation of preparative amounts of plasmid DNA without the use of cesium chloride centrifugation is described. The protocol uses the alkaline extraction procedure and an exclusion column of Fractogel TSK 75S. From a clear lysate it is possible to obtain plasmid DNA completely free of proteins, RNA, and chromosomal DNA. From partially purified plasmid the procedure allows the separation of the different forms. This technique was successfully applied to different plasmids ranging in size from 2.9 to 17.5 MDa. It is a preparative method yielding easily 500 micrograms of pBR322 from 1 liter of amplified culture. The plasmid is suitable for
topoisomerase I
,
topoisomerase
II, and EcoRI assays.
...
PMID:Purification and separation of various plasmid forms by exclusion chromatography. 244 30
CHO-Cdr20 cells are 10-20 times more resistant to killing by cadmium than the parental CHO cells. Resistance has been linked to amplification of the metallothionein genes MT-I and MT-II and their coordinate induction by cadmium and other toxic metals. We studied the roles of the nuclear enzymes
topoisomerase I
and
topoisomerase
II in Cd-induced expression of MT-II. Camptothecin-induced DNA strand breakage, mediated by
topoisomerase I
in cells, increased by approximately 20% when the resistant cells were incubated first with 50 microM Cd and then with camptothecin. Short DNA fragments were enriched in MT-II-hybridizing sequences, indicating that
topoisomerase I
-associated breakage was directed in part toward the location of induced gene activity. Ten microM camptothecin inhibited Cd-induced accumulation of MT-II mRNA as well as induced and uninduced RNA synthesis in the resistant cells. These data are consistent with the notion that
topoisomerase I
participates in most or all forms of RNA synthesis. Topoisomerase II inhibitors which trap cleavable complexes (amsacrine, VM-26, VP-16) increased DNA strand breakage at very high concentrations (50-100 microM); the increased breakage appeared to be concentrated near the MT-II gene. This class of inhibitor did not block the accumulation of MT-II message. Novobiocin, a second type of
topoisomerase
II inhibitor blocked transcription at 300 microM. Merbarone, a novel, third type of
topoisomerase
II inhibitor, blocked MT-II transcription at 50-100 microM. The latter two inhibited total RNA synthesis in induced, but not uninduced cells. Thus, it is possible that
topoisomerase
II plays more than one role in transcription and that more than one form of this enzyme is involved.
...
PMID:Evidence for the participation of topoisomerases I and II in cadmium-induced metallothionein expression in Chinese hamster ovary cells. 247 39
A 4-h posttreatment with 4 microM beta-lapachone was previously shown to enhance the lethality of X-rays against human laryngeal epidermoid carcinoma (HEp-2) cells (D. A. Boothman et al., Cancer Res., 47:5361-5366, 1988). We now show that beta-lapachone (a) activates the DNA-unwinding activity of
topoisomerase I
, (b) inhibits the fast component of potentially lethal damage repair (PLDR) carried out by HEp-2 cells when present during or immediately following X-irradiation, (c) specifically and synergistically enhances the cytotoxic effects of DNA-damaging agents which induce DNA strand incisions, such as neocarzinostatin or X-rays, against a radioresistant human malignant melanoma (U1-Mel) cell line, (d) does not synergistically potentiate melphalan-induced lethality against U1-Mel cells but inhibits survival recovery and increases sister chromatid exchanges, and (e) does not further enhance the lethal effects of X-rays following prolonged drug exposures, indicating that beta-lapachone modifies initially created DNA lesions or inhibits lesion repair but does not create lethal lesions by itself. beta-Lapachone accelerated the DNA-unwinding activity of
topoisomerase I
derived from avian erythrocytes, calf thymus, or HEp-2 cells. beta-Lapachone did not intercalate into DNA, nor did it inhibit
topoisomerase
II or ligation carried out by mammalian or T4 DNA ligases. Structurally similar analogues, alpha-lapachone, lapachol, and dichloroallyl lawsone, did not enhance X-ray-induced cytotoxicity nor did they activate
topoisomerase I
. Camptothecin, a specific inhibitor of
topoisomerase I
, significantly radiosensitized HEp-2 cells, in a manner similar to beta-lapachone. These results suggest a role of
topoisomerase I
in DNA repair. The PLDR capacity of confluent-arrested HEp-2 cells was inhibited when beta-lapachone was given immediately following or during X-irradiation. The effect decreased when the drug was added at later times. beta-Lapachone may enhance lethality by converting single- into double-stranded DNA breaks during PLDR or through DNA conformational changes which inhibit PLDR. We propose that either mechanism of enhanced lethality may result from the ability of beta-lapachone to activate
topoisomerase I
.
...
PMID:Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I. 253 61
A complementary DNA fragment of the human DNA topoisomerase II gene was cloned into a T7 expression vector and overproduced in Escherichia coli. Rabbit polyclonal antibodies were raised against the recombinant
topoisomerase
II polypeptide which corresponds to the C-terminal one-third of human
topoisomerase
II polypeptide. Using the antiserum, DNA topoisomerase II levels were measured by immunoblotting human lymphocytes following phytohemagglutinin (PHA) stimulation. Our results showed that the intracellular
topoisomerase
II but not the
topoisomerase I
level increased in parallel with the entry of cells into proliferation. At least a 100-fold increase in
topoisomerase
II was observed at 50 h after PHA stimulation. As
topoisomerase
II levels increased upon PHA stimulation, DNA damage induced by teniposide (VM26) increased in parallel, as measured by both DNA synthesis inhibition and chromosomal aberrations. However, the damage induced by camptothecin also increased upon PHA stimulation, while the level of
topoisomerase I
remained relatively constant. Our results suggest that, in addition to cellular contents of topoisomerases, the state of cell proliferation is another important determinant of drug action.
...
PMID:Studies of topoisomerase-specific antitumor drugs in human lymphocytes using rabbit antisera against recombinant human topoisomerase II polypeptide. 253 95
The biological effects of a number of DNA ligands which interact with the minor groove of B-form DNA (e.g. netropsin, distamycin and Hoechst 33258) are thought to arise from the direct disturbance of the processes of DNA replication and transcription. Although ligand binding appears to be an important factor in cytotoxicity, the pathways by which drug molecules can be actively dissociated from nuclear DNA are unknown. Recent evidence suggests that minor groove ligands can distort the manner in which DNA associates with nucleosomal core particles and we have hypothesized that in an intact cell such imposed torsional stress could be subject to the action of cellular topoisomerases. We have used flow cytometry to study the effects of various inhibitors (including
topoisomerase
-interactive drugs) on the responses of a mutant cell line (HoeR415) to Hoechst 33342, given that the mutant shows resistance to the cytotoxicity of this DNA-specific dye due to an enhanced capacity to dissociate nuclear DNA-dye complexes. Ligand-DNA dissociation in the mutant was found to be energy-dependent but not specifically, affected by the drug-efflux blocker verapamil or by inhibitors of DNA synthesis. The
topoisomerase
II inhibitors novobiocin, VP16, nalidixic acid and the
topoisomerase I
-interactive drug camptothecin inhibited ligand-DNA dissociation to various extents with novobiocin being the most effective (100% inhibition at 1 mM). Both novobiocin and camptothecin were without effect on the nuclear loss of a DNA intercalator, adriamycin. We conclude that efficient
topoisomerase
activity is required for the active dissociation of DNA minor groove-ligand complexes.
...
PMID:A role of DNA topoisomerases in the active dissociation of DNA minor groove-ligand complexes. A flow cytometric study of inhibitor effects. 253 63
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>